AIRLINK 60.35 Increased By ▲ 0.50 (0.84%)
BOP 6.34 Increased By ▲ 0.04 (0.63%)
CNERGY 4.47 Increased By ▲ 0.09 (2.05%)
DFML 16.09 Increased By ▲ 0.12 (0.75%)
DGKC 72.01 Increased By ▲ 0.31 (0.43%)
FCCL 18.62 Increased By ▲ 0.16 (0.87%)
FFBL 26.46 Increased By ▲ 0.16 (0.61%)
FFL 9.41 Increased By ▲ 0.21 (2.28%)
GGL 10.47 Increased By ▲ 0.15 (1.45%)
HBL 115.86 Increased By ▲ 1.36 (1.19%)
HUBC 113.65 Increased By ▲ 0.95 (0.84%)
HUMNL 6.75 Increased By ▲ 0.10 (1.5%)
KEL 4.93 Increased By ▲ 0.10 (2.07%)
KOSM 4.70 Increased By ▲ 0.02 (0.43%)
MLCF 39.05 Increased By ▲ 0.06 (0.15%)
OGDC 124.70 Increased By ▲ 1.30 (1.05%)
PAEL 22.20 Increased By ▲ 0.20 (0.91%)
PIAA 11.14 Increased By ▲ 0.14 (1.27%)
PIBTL 6.13 Increased By ▲ 0.11 (1.83%)
PPL 110.41 Increased By ▲ 2.01 (1.85%)
PRL 28.61 Increased By ▲ 0.41 (1.45%)
PTC 11.28 Increased By ▲ 0.21 (1.9%)
SEARL 52.51 Increased By ▲ 1.06 (2.06%)
SNGP 68.50 Increased By ▲ 0.50 (0.74%)
SSGC 11.75 Increased By ▲ 0.15 (1.29%)
TELE 8.25 Increased By ▲ 0.18 (2.23%)
TPLP 11.84 Increased By ▲ 0.14 (1.2%)
TRG 75.05 Decreased By ▼ -0.66 (-0.87%)
UNITY 23.55 Increased By ▲ 0.80 (3.52%)
WTL 1.31 Increased By ▲ 0.03 (2.34%)
BR100 6,634 Increased By 88.3 (1.35%)
BR30 22,597 Increased By 298.9 (1.34%)
KSE100 64,389 Increased By 685.4 (1.08%)
KSE30 21,794 Increased By 285.6 (1.33%)
Business & Finance

Pharma giant GSK says ‘no basis' for paracetamol bribe allegations

  • Pakistan Young Pharmacist Association says regulatory officials received bribes to register globally banned paracetamol 665mg
Published May 20, 2022

Pharmaceutical giant GSK has rejected allegations levelled by the Pakistan Young Pharmacist Association (PYPA), which claimed that senior officials of the Drug Regulatory Authority Pakistan (DRAP) received bribes to register globally banned paracetamol 665mg at an exorbitant price in the country.

Earlier this month, Furqan Ibrahim, general secretary of PYPA, in a letter to the PM said senior DRAP officials illegally allowed heavy advertisement of the painkiller.

Ibrahim said Panadol 665mg, made my GSK and sold as Panadol Extend, was registered in Pakistan even though European countries have banned the drug. “These are extremely evil affairs of the DRAP mafia; they do not bother about the lives of Pakistanis just for money and register those drugs in Pakistan, which are banned all over the world due to serious side effects,” read the letter.

DRAP received ‘bribe’ to register ‘globally-banned paracetamol’, claims PYPA

Responding to the allegations, GSK in its notice to the bourse on Friday said, “We are aware of the allegations made by the Young Pharmacists Association against DRAP, GSK and various other organisations etc. While we see no basis for these allegations, we take all concerns seriously and where appropriate, we will take the required actions.”

The pharma giant said that paracetamol is the active ingredient in popular pain relief medicines such as Panadol and is widely available in various strengths and formulations for children and adults. “Numerous studies show that paracetamol is a suitable and effective treatment for the whole family when used as directed,” it said.

GSK reiterated that Panadol Extend (665 mg modified-release paracetamol) offers “clinically proven treatment option” and is available in countries globally, “including countries in Europe (such as Denmark and Finland) and in New Zealand and Australia.”

PYPA also claims the shortage of Panadol 500mg tablet in the market is part of efforts to convert patients to Panadol 665mg, which costs more.

GSK however rejected this and stated: “Following an increase in demand for Panadol we have immediately responded with increased production and supply remains strong from our factories.”

Comments

Comments are closed.